Sparrow Pharmaceuticals
Ejecutivos
Ver el organigrama con sus 9 ejecutivos principales
Biografías más buscadas en Sparrow Pharmaceuticals
- Robert Jacks, Director, President and Chief Executive Officer
- Niall O'Donnell, Director
- Peter Thompson, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Sparrow Pharmaceuticals.
Farmacia
Sparrow Pharmaceuticals tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Expands PROST! with Fourth Cohort in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Announces First Patient Rolled-Over to Open-Label Extension of RESCUE, a Phase 2 Clinical Trial of SPI-62 for ACTH-Dependent Cushing’s Syndrome — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Presents ePoster on SPI-62 at the 25th European Congress of Endocrinology — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022 — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial of SPI-62 for Cushing’s Syndrome — Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica — Sparrow Pharmaceuticals
- View more press releases Close
Redes sociales sobre Sparrow Pharmaceuticals
- Sparrow Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Sparrow Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Robert Jacks 
Llame a Sparrow Pharmaceuticals al +1 617...
